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Objectives: Polymerase chain reaction (PCR) techniques could provide an ear-
lier diagnosis than traditional techniques (TT) to identify chronic infections in 
patients with musculoskeletal implants. The aim was to determine costs associ-
ated to microorganism’s diagnosis in sonicate samples of musculoskeletal implants, 
comparing the addition of a PCR technique (UnyveroTM i60-ITI) to TT versus TT 
only. MethOds: A preliminary cost analysis was developed to estimate the hos-
pital costs in patients admitted at Fundación Jimenez Diaz Hospital (May-2014 to 
April-2015) for musculoskeletal implant removal due to chronic infection suspect. 
Sonicated samples were tested for microbiological diagnosis using TT. Additionally, 
samples were tested using UnyveroTM i60-ITI. Medical hospitals records were 
reviewed for data collection: sociodemographic data; type, dosing and antibiotic 
treatments; and hospital length of stay (LOS). Intravenous vancomycin and cef-
tazidime were selected as the initial empiric treatment. Replacement to a specific 
antibiotic was performed after microbiological diagnosis. Total estimated costs (€ , 
2015) included antibiotic treatment, hospital stay (€ 1,006 per day) and UnyveroTM 
i60-ITI kits (€ 350 per kit) costs. Results: Ten patients were retrieved for prelimi-
nary analysis (average age: 75.39±6.31 years; 20% men). Hip (40%) and knee (40%) 
were the most frequent implant sites. Average period from implant removal to final 
diagnosis lasted 4.60±1.35 days with TT. UnyveroTM i60-ITI diagnosis was available 
24h after removal. LOS was 24.4 days for TT and 23.3 days for UnyveroTM i60-ITI 
added to TT. The average antibiotic treatment cost was € 1,016.01 for TT and € 976.84 
for UnyveroTM i60-ITI added to TT. Hospital stay cost was € 25,591.26 for TT and 
€ 24,361.98 for UnyveroTM i60-ITI added to TT. The use of UnyveroTM i60-ITI reduced 
average total costs in € 840.67. cOnclusiOns: UnyveroTM i60-ITI PCR for microbio-
logical identification in musculoskeletal implants sonicated is associated to faster 
diagnosis and shorter hospital stays than traditional techniques only, allowing cost 
savings at hospital level.
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Objectives: To perform economic evaluation of donor breast milk (DBM) (using 
clinical breast pump) or artificial formula (AF) for premature infants in the neonatal 
intensive care unit (NICU) for Russian healthcare setting. MethOds: We calculated 
the cost of providing 100 ml of DBM using clinical breast pump and 100 ml of AF for 
premature infants in the NICU. The total cost of providing DBM was measured as: 
the breast pump cost, the individual pumping set cost and staff costs. The cost of 
providing AF was calculated using the mean cost per 100 ml for powdered AF and 
staff costs. We also calculated the cost per averted case of necrotizing enterocolitis 
(NE) for premature infant when breastfeeding instead of the AF is used. The cost 
of the averted NE was obtained using the difference in cost of feeding during the 
period, required for NE development and number of patients “needed to treat” (NNT) 
to prevent 1 NE case derived from the clinical trials. Besides we calculated the DBM 
cost when breast milk fortifier (BMF) is added for low-weight infants. Results: The 
costs per 100 ml of AF and DBM were similar (0,67 EUR and 0,77 EUR respectively). 
The cost per averted case of NE was 344,5 EUR within 35 days that is less than NE 
treatment. The difference in costs (in favor of AF) amounted to 2,87 EUR per 100 ml 
with the use of BMF. cOnclusiOns: The cost of DBM is comparable to the cost of 
AF, with a significant DBM clinical benefit. The costs per averted NE within 35 days 
shows that DBM is acceptable from the position of Russian health care system. 
When calculating the costs of DBM with the use of BMF, DBM costs exceed those 
for AF for more than 5 times.
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Objectives: The material cost for reusing intermittent urinary catheters is lower 
than to use single-use catheters. These cost savings are misleading since com-
plications may increase and lower compliance to the therapy can be expected, 
necessitating use of the second choice therapy form with even more complica-
tions, i.e. an indwelling catheter. The purpose of this cost-comparison study was 
to compare single-use of coated catheters to re-use of non-coated catheters in a 
group of individuals performing intermittent catheterization where some of them 
fail their first choice therapy and switch to an indwelling catheter. MethOds: A 
1-year Markov simulation model with monthly cycles was developed for users of 
daily intermittent catheterization. Individuals who used 4 catheters/day (single-use) 
were compared to individuals who re-used their catheters (1 catheter/day). After 
one month’s use, 18% of the patients in the single-use group were assumed to fail 
their treatment and switch to indwelling catheter. The corresponding frequency in 
the re-use group was 35%. The model was populated with risks from the literature 
for complications (e.g. symptomatic UTI, UTI resistant to antibiotics, pyelonephritis, 
bacteremia, epididymitis, strictures, bladder stones) as well as catheter and health-
care costs for single-use, re-use and indwelling catheters, respectively. Results: 
The total annual catheter cost per patient was 2188 euros (including 163 euros for 
indwelling catheters) in the single-use group and 817 euros (including 317 euros 
for indwelling catheters) in the re-use group. The total annual cost per patient for 
PMD38
Do not overlook yoUr CoUntry-sPeCifiC ChArACteristiCs: the CAse of 
BAroreflex ACtivAtion therAPy (BAt) for the treAtMent of resistAnt 
hyPertension
Soto M, Llach K, Sampietro-Colom L
Hospital Clínic Barcelona, Barcelona, Spain
Objectives: To assess clinical effectiveness, cost-effectiveness, and budget impact 
of Baroreflex Activation Therpay (BAT) in comparison with optimal medical treat-
ment from a hospital and societal perspective in Spain. MethOds: Clinical effec-
tiveness analysis was based on studies collected from medical databases and grey 
literature. Cost effectiveness and budget impact analysis was based on a Markov 
model using epidemiological data, risk functions and clinical management in 
Spain. Results: In a simulated cohort of 55-year-old non-smoker Spanish patients 
with resistant hypertension, BAT significantly reduced the number of heart attacks, 
heart failures, strokes, end-of-stage renal disease and liver transplantations. BAT 
produced 0.78 additional quality-adjusted life years with an incremental societal 
cost of 50.400€ . The resulting incremental cost-effectiveness ratio (65.000€ per 
QALY) was substantially larger than the one estimated for the Northern European 
population (7.800€ per QALY). Qualitative results were robust to all-parameter vari-
ations. cOnclusiOns: Local health characteristics –both, epidemiological data and 
clinical management– have a large weight on cost-effectiveness results.
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Objectives: The objective of this study was to compare the one-year costs 
related to cardiac adverse events post-index procedure discharge of Absorb and 
Xience. MethOds: Using resource use data from ABSORB II, which comprised of 
501 patients randomized 2:1, one-year cardiac-related adverse event costs were 
calculated for the Absorb and Xience groups in 5 countries (France, Germany, 
Italy, The Netherlands, and Spain). Unit costs from the perspective of the health 
system were taken from publicly available data sources (2014 level). Costs were 
calculated by lipid control and diabetic status, both at baseline. Resource use 
categories included hospital admissions, outpatient visits, and cardiac diagnostic 
tests. Results: Mean country costs ranged between 1,140-1,880 Euros for Absorb 
and between 1,310-2,420 Euros for Xience. Mean country-specific per patient cost 
differences (Absorb minus Xience) were 170 Euros in France, 220 Euros in The 
Netherlands, 250 Euros in Germany, 420 Euros in Italy, and 540 Euros in Spain. 
Cost-savings were mainly attributable to the 1.5 unit reduction in mean num-
ber of subsequent percutaneous coronary interventions (PCIs) performed in the 
Absorb arm compared to the Xience group (32 versus 47 per 1,000 population for 
all country data combined). Regardless of lipid status (lipids < 2.0 mmol/l or lipids 
> 2.0 mmol/l) and diabetic status at baseline, cardiac-related adverse event costs 
were reduced with Absorb. Patients with a lipid profile > 2.0 mmol/l at baseline 
had mean country costs that ranged between 1,240-1,930 Euros for Absorb and 
between 1,380-2,540 Euros for Xience. Patients with diabetes at baseline had mean 
country costs that ranged between 1,250-1,920 Euros for Absorb and between 
1,380-3,190 Euros for Xience. cOnclusiOns: These findings suggest potential 
short term cost-savings with Absorb compared to Xience as a result of the reduced 
mean number of repeat PCIs. Future research is necessary to study total direct and 
indirect cost and long-term costs of each intervention.
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Objectives: ISO 15197:2003, states that 95% of the glucose results shall fall within 
±15 mg/dl for concentrations ≤ 75 mg/dl and within ±20% for > 75 mg/dl. Some 
measures which may fall into the recommended thresholds would be out of the 
limits of good metabolic control, not permitting to adjust the therapy, increas-
ing the complication risk, and raising the associated costs. The objective was 
to estimate the annual cost saving in Spain by using glucose meters with better 
accuracy. MethOds: Two samples of true and read values were created accord-
ing to type 1 and 2 diabetes (T1D, T2D) Spanish population data. Proportion of 
readings into the recommended thresholds whose true values were out of the 
limits was calculated. The complication risk associated with those false readings 
was estimated from the clinical trials, and the cost to manage complications was 
calculated from public costs. Cost of strips was included to estimate the total cost. 
The annual cost saving was the difference between the total cost (2015 € ) of all 
Spanish patients in the base case (accuracy level, A20%) and other scenarios (A15%, 
A10%, and A5%). Results: 100% of T1D (n: 116,160) and 32.2% of T2D patients (n: 
957,511) will often need glycaemic self-monitoring, with a cost around 168 mill€ . 
Not detected hyper/hypoglycemia values were estimated: 119,302; 81,025, 55,915 
and 27,332 in A20%, A15%, A10%, and A5%, respectively. Total cost was 193.94 mill€ ; 
183.94 mill€ , 178.29 mill€ , and 172.98 mill€ , respectively, leading a saving cost of 
10.006 mill€ , 15.657 mill€ and 20.960 mill€ , by changing from A20% to A15%, A10% 
and A5% scenario. cOnclusiOns: Blood glucose meters with better accuracy 
leads to decrease complications risk which is associated with cost savings: when 
meters accuracy increases from 20% to 15% and 10%, cost savings are 5.9%, 9.3%, 
and 12.4% on total strips cost.
